Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR8518261

— · C

7adc642b-a44b-51ea-873b-c9eb0fac550c

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
C
subtype
C

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_GAMMA_RESPONSE+0.410
  • ALLOGRAFT_REJECTION+0.400
  • APOPTOSIS+0.390
  • TNFA_SIGNALING_VIA_NFKB+0.390
  • INTERFERON_ALPHA_RESPONSE+0.380
  • PI3K_AKT_MTOR_SIGNALING+0.380
  • INFLAMMATORY_RESPONSE+0.360
  • KRAS_SIGNALING_UP+0.340
  • IL2_STAT5_SIGNALING+0.320
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.310

Top 10 suppressed

  • MYC_TARGETS_V2-0.460
  • E2F_TARGETS-0.280
  • OXIDATIVE_PHOSPHORYLATION-0.250
  • DNA_REPAIR-0.230
  • MYC_TARGETS_V1-0.230
  • NOTCH_SIGNALING-0.220
  • G2M_CHECKPOINT-0.160
  • MYOGENESIS-0.140
  • SPERMATOGENESIS-0.140
  • ADIPOGENESIS-0.070

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
116edbdd6-190c-4051-a957-4c048aa7ed2e
melanoma-umap@29
——0.877
2BS_55JW3HFM
brain-umap@2
Ganglioglioma—0.861
3SRR8518191
breast-umap@18
—D0.860
4BS_014EVM2D
brain-umap@2
low-grade glioma—0.844
5MNG19
mng-umap@100
——0.840
6s0122206
melanoma-umap@29
——0.840
7TCGA-CN-5369-01A-01R-1436-07
head-neck@1
——0.840
8bd09bf00-3fb3-41fc-ae4d-4ac68a925a6b
melanoma-umap@29
——0.839
9BS_52426AMF
brain-umap@2
low-grade glioma—0.839
10TCGA-F7-8489-01A-31R-2403-07
head-neck@1
——0.837

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 37 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_GAMMA_RESPONSE0.410Idelalisib— uncovered
ALLOGRAFT_REJECTION0.400Idelalisib— uncovered
APOPTOSIS0.390Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.390Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.380Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.380Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.360Idelalisib— uncovered
KRAS_SIGNALING_UP0.340Inavolisib— uncovered
IL2_STAT5_SIGNALING0.320Idelalisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.310Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.280Inavolisib— uncovered
COMPLEMENT0.260Inavolisib— uncovered
PANCREAS_BETA_CELLS0.260Cobimetinib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.250Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.240Remibrutinib— uncovered
APICAL_SURFACE0.230Temsirolimus— uncovered
COAGULATION0.230Binimetinib— uncovered
ESTROGEN_RESPONSE_LATE0.230Idelalisib— uncovered
PROTEIN_SECRETION0.230Remibrutinib— uncovered
TGF_BETA_SIGNALING0.220Inavolisib— uncovered